Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials

OBJECTIVE: Tofacitinib is an oral, small-molecule Janus kinase inhibitor that is being investigated for IBD. We evaluated the efficacy and safety of tofacitinib for induction and maintenance treatment in patients with moderate-to-severe Crohn's disease (CD). DESIGN: We conducted two randomised,...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Gut
Auteurs principaux: Panés, Julian, Sandborn, William J, Schreiber, Stefan, Sands, Bruce E, Vermeire, Séverine, D'Haens, Geert, Panaccione, Remo, Higgins, Peter D R, Colombel, Jean-Frederic, Feagan, Brian G, Chan, Gary, Moscariello, Michele, Wang, Wenjin, Niezychowski, Wojciech, Marren, Amy, Healey, Paul, Maller, Eric
Format: Artigo
Langue:Inglês
Publié: BMJ Publishing Group 2017
Sujets:
Inflammatory Bowel Disease
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5532457/
https://ncbi.nlm.nih.gov/pubmed/28209624
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/gutjnl-2016-312735
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires